O III Seminário Anual Científico e Tecnológico de Bio-Manguinhos foi planejado para ser um hub para cientistas, empreendedores e empresas de biotecnologia para acelerar o desenvolvimento de soluções inovadoras para a saúde da população.
To discuss the main challenges in research, development and innovation in vaccines, biopharmaceuticals and diagnostic reagents, students, researchers and specialists gathered at the third edition of the Annual Scientific and Technological Seminar of Bio-Manguinhos, held from May 4 to 7, 2015, at the Museu da Vida, Fiocruz.
Confira os destaques do III Seminário Anual Científico e Tecnológico de Bio-Manguinhos
At the opening table of the event, the director of Bio-Manguinhos, Artur Couto, reinforced the importance of the event to stimulate research and innovation in the country, recalling the 39 years of the Institute, celebrated on May 4. “This seminar is strategic and is part of our challenge to create a strong scientific base. Clearly, the quality of the work has been growing and is the result of all the effort and dedication of the teams”, he reinforced.
The director of the Evandro Chagas Institute, Pedro Fernando Vasconcelos, presented the lecture “Arboviruses: risks for the country and challenges in diagnosis and prevention”, on the morning of the second day of the event. More than 16,000 viruses from 200 different arboviruses have been isolated, from 1954 to 2014. Of these, 34 are related to diseases in humans, such as those cited at the beginning of this story. “Seven are associated with epidemics . The most recent member of this clan is chikungunya,” said Vasconcelos.
On the afternoon of 5/5, the researcher from the Brazilian Agricultural Research Corporation (Embrapa), Elibio Rech, pointed out the possibility of partnerships between his institution and the pharmaceutical industry.
The last day of the meeting ended with the award ceremony of the scientific poster exhibition.